By Sheri Kasprzak
New York, Feb. 6 - Advaxis, Inc. said it has settled a private placement of secured convertible debentures for $3 million.
The company issued the three-year debentures to Cornell Capital Partners, LP.
The 6% debentures are convertible into common shares at the lesser of $0.287 each or 95% of the lowest volume weighted average price of the company's stock for the 30 trading days before conversion.
Cornell will receive warrants for 4.2 million shares, exercisable at $0.287 each, and warrants for 300,000 shares, exercisable at $0.344 each.
At closing, Advaxis received $1.5 million in proceeds and will receive the other half once it files a registration statement with the Securities and Exchange Commission.
Proceeds will be used to advance the clinical development of the company's Lovaxin C product for cancer.
Princeton, N.J.-based Advaxis is a biopharmaceutical company focused on developing Listeria-based cancer vaccines and other cancer therapies.
| Issuer: | Advaxis, Inc.
|
| Issue: | Secured convertible debentures
|
| Amount: | $3 million
|
| Maturity: | Three years
|
| Coupon: | 6%
|
| Price: | Par
|
| Yield: | 6%
|
| Conversion price: | The lesser of $0.287 or 95% of the VWAP of the company's stock for the 30 trading days before conversion
|
| Warrants: | For 4.5 million shares
|
| Warrant strike price: | $0.287 for 4.2 million shares; $0.344 for 300,000 shares
|
| Investor: | Cornell Capital Partners, LP
|
| Settlement date: | Feb. 2
|
| Stock symbol: | OTCBB: ADXS
|
| Stock price: | $0.24 at close Feb. 2
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
